MINNEAPOLIS (April 23, 2018) – Inspire Medical Systems, Inc. (“Inspire”), a medical technology
company focused on the development and commercialization of innovative and minimally invasive
solutions for patients with obstructive sleep apnea, announced today that it has commenced an initial
public offering of 5,000,000 shares of its common stock. Inspire also expects to grant the underwriters a
30-day option to purchase an additional 750,000 shares of its common stock. The initial public offering
price is expected to be between $14.00 and $16.00 per share. All shares of common stock to be sold in the
proposed offering will be sold by Inspire. Inspire has been approved to list its common stock on the New
York Stock Exchange under the ticker symbol “INSP.”
BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint book-running managers for the
proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-managers
for the proposed offering.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating
to this offering, when available, may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North
College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email:
email@example.com; and from Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities
and Exchange Commission but has not yet become effective. These securities may not be sold nor may
offers to buy these securities be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical
Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that
provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Inspire Investor and Media Contact